Skip to main content

Table 1 Study characteristics

From: Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis

Study, Year

Publication Type

Study Design

Study Sites (n)

Patients (n)

Quality Score

Risk of Bias Assessment

Al-Majzoub et al., 2016 [20]

Manuscript

Retrospective cohort

1

53

6

Moderate

DeAngelo et al., 2018 [22]

Manuscript

Retrospective cohort

2

89

6

Moderate

Fischer et al., 2018 [24]

Manuscript

Retrospective cohort

22

103

6

Moderate

Holt et al., 2018 [25]

Manuscript

Retrospective cohort

5

134

6

Moderate

Jones et al., 2016 [27]

Manuscript

Retrospective cohort

4

148

6

Moderate

Kuroski et al., 2017 [28]

Manuscript

Retrospective cohort

1

137

6

Moderate

Mangram et al., 2016 [30]a

Manuscript

Retrospective cohort

2

61*

6

Moderate

Margraf et al., 2020 [31]

Manuscript

Retrospective cohort

1

80

Mohan et al., 2018 [32]

Manuscript

Retrospective cohort

2

128

6

Moderate

Voils et al., 2015 [33]

Manuscript

Retrospective cohort

1

165

6

Moderate

Cang et al., 2014 [21]

Abstract

Retrospective cohort

1

NR

4

High

Di Napoli et al., 2014 [23]

Abstract

Retrospective cohort

3

69

5

High

Kotsianas et al., 2015 [26]

Abstract

Retrospective cohort

3

91

6

Moderate

Peck et al., 2016 [29]

Abstract

Retrospective cohort

1

89

5

High

Wagner et al., 2019 [34]

Abstract

Retrospective cohort

(many)

250

5

High

  1. a Most of this study characteristics include data from three rivaroxaban patients
  2. We did not do the quality assessment of our previous work marked as “--”